Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.78 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.78 |
| ▸ | MGLL | Q99685 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.48 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136672 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL13184389 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL131963 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL1916980 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL22531036 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL7754480 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL7191252 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL135634 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL8388580 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A | |
| SCHEMBL8822087 | 1.00 | BCL9 (0.78) | BCL9CTNNB1MGLLALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551228-B1 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | UNIV NEW YORK (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252909-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-8211859-B2 | α-galactoceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2011-02-03 | — | — | US | disclosed |
| WO-2008047249-A9 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008047249-A9 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-12-23 | — | — | WO | disclosed |
| EP-2099813-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Centre National de la Recherche Scientifique (FR) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008047249-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047249-A2 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-04-24 | — | — | WO | disclosed |
| US-7273852-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1551228-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | New York University (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2004-07-01 | — | — | US | disclosed |
| WO-2003105769-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | UGT8, UGCG, SGMS1 | BCL9 136/4885CTNNB1 4065/4885MGLL 1911/4885 |
| US-20110028411-A1 | ALPHA-GALACTOCERAMIDE ANALOGS, THEIR METHODS OF MANUFACTURE, INTERMEDIATE COMPOUNDS USEFUL IN THESE METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GALE, GALNT14, GALC | BCL9 1798/4885CTNNB1 3979/4885MGLL 167/4885 |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | CCR8, UGT8, H1-10 | BCL9 264/4885CTNNB1 4226/4885MGLL 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.